Further, tumor-derived sEVs inhibit CD8+ T cell SLC6A8 (solute carrier family 6 member 8) dependent creatine import in NPM-1 mutated AML cells through the transfer of miR-19a-3p (41). Here, SLC6A8 is linked to neoplasm.